๐ŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
CRISPR Therapeutics AG (CRSP)
NASDAQ: CRSP ยท Real-Time Price ยท USD
39.24
+0.31 (0.80%)
Nov 20, 2026, 2:38 PM EST - Market open

CRISPR Therapeutics AG Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
25.173.5137.31371.211.2914.96
Revenue Growth
-34.34%-90.59%-89.95%30885.48%-99.87%127154.94%
Gross Profit
-447.18-494.78-393.59-146.38-570.7473.22
Operating Income
-518.18-568.32-466.57-222.54-673.16373.53
Net Income
-456.14-581.6-366.25-153.61-650.18377.66
Earnings Per Share
-4.75-6.47-4.34-1.94-8.364.70
EPS Growth
------

Revenue by Segment

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Collaboration
--353700.44913.08
Grant
1.853.512.311.210.761.88
Revenue (Total)
25.173.5137.31371.211.2914.96

Cash & Debt

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
2,2771,9761,9041,6961,8682,379
Total Debt
779.83206.75223.69238.63244.02225.03
Net Cash (Debt)
1,4971,7691,6801,4571,6242,154
Net Cash Growth
-13.64%5.29%15.31%-10.30%-24.59%32.24%
Net Cash Per Share
15.5719.6719.9218.3920.8926.79

Cash Flow & CapEx

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-374.63-345.01-142.77-260.38-495.74538.97
Capital Expenditures
-2.08-0.91-1.9-9.47-37.19-81.71
Free Cash Flow
-376.72-345.93-144.68-269.85-532.93457.27
Free Cash Flow Growth
------

Margins

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
----39.43%-51.72%
Operating Margin
-2058.55%-16191.40%-1250.38%-59.95%-56190.40%40.82%
Pretax Margin
-1802.19%-16466.24%-971.93%-40.60%-54298.83%41.48%
Profit Margin
-1812.07%-16569.77%-981.54%-41.38%-54271.70%41.28%
FCF Margin
-1496.56%-9855.50%-387.72%-72.69%-44484.89%49.98%

Valuation

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingNov '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
-----15.36
P/FCF Ratio
-----12.68
PS Ratio
152.561423.8090.0313.402656.646.34